- Concurrently, the Company Has Issued a Press Release Announcing the
Presentation of Clinical Experience Data for NUPLAZID at the American
Academy of Neurology (AAN) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2018--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today issued the following
NUPLAZID® (pimavanserin) is the only medicine approved in the
United States to treat hallucinations and delusions associated with
Parkinson’s disease psychosis. NUPLAZID was approved by the FDA based on
a pivotal Phase 3 study that demonstrated clinically robust and highly
statistically significant efficacy, combined with other supportive
studies. We are confident in NUPLAZID’s efficacy and positive
benefit/risk profile and stand firmly behind it.
ACADIA’s top priority has been, and continues to be, patient safety.
NUPLAZID was approved and launched in 2016. As the manufacturer of a
newly launched drug, we are routinely in contact with the FDA regarding
requests for additional information on NUPLAZID, including postmarketing
safety surveillance information as part of the FDA’s ongoing safety
In a statement released to the media on April 10, 2018, the FDA stated,
“The FDA continues to monitor adverse events reported with NUPLAZID that
are submitted to the FDA Adverse Event Reporting System (FAERS). We have
noted that the cases typically involve geriatric patients with
advanced-stage Parkinson’s disease, as well as numerous medical
conditions, who are frequently taking concomitant medications with risks
for serious adverse events, including death. Based on these data, the
FDA has, at this time, not identified a specific safety issue that is
not already adequately described in the product labeling.”
On April 25, 2018, the FDA stated that its evaluation does not mean the
Agency has determined the medicine has a new risk and does not suggest
healthcare providers should not prescribe it nor that patients should
stop taking the medication. The Agency also has confirmed this statement
does not represent a change from the safety review and monitoring
activities the FDA referred to in its statement of April 10. As always,
we will continue to work with the FDA and medical community to answer
any questions related to NUPLAZID.
ACADIA collects and analyzes postmarketing events for NUPLAZID as part
of our ongoing commitment to monitor the medication’s safety profile.
These events are submitted to the FDA and incorporated into the FDA’s
FAERS public reporting system. Because NUPLAZID is distributed through a
specialty distribution channel, we have frequent (in most cases monthly)
contact with patients and caregivers through our distribution partners.
This increased interaction naturally results in dramatically higher
adverse event collection and reporting compared to products without such
a distribution method. Approximately 93 percent of the reported adverse
events associated with NUPLAZID are considered “solicited” due to this
direct interaction with patients and caregivers, while only
approximately 7 percent of these events are considered “spontaneous”
reports, which are voluntary reports originating from consumers or
healthcare professionals. In contrast, most other antipsychotics are
distributed through retail channels, which rely almost entirely on
“spontaneous” reporting. Consequently, only a small fraction of actual
adverse events are collected for these drugs.
NUPLAZID Recent Studies Update
Since NUPLAZID’s approval, additional studies have further demonstrated
its efficacy and benefit/risk profile. Simultaneous with this release,
ACADIA announced the results of two independent studies presented this
week at the American Academy of Neurology Annual Meeting. In the first
study, a retrospective 102-patient chart review conducted by researchers
at Vanderbilt University Medical Center, more than 70 percent of all
patients treated with NUPLAZID reported clinical improvement, while 88
percent of patients treated longer than four weeks improved.
Importantly, NUPLAZID was tolerated without significant side effects in
the majority of patients. In this study, there was no increase in
mortality reported for patients taking NUPLAZID. The second study,
conducted by researchers from the Parkinson’s Disease and Movement
Disorders Center at Henry Ford Hospital, involved a survey of real-life
experience among 16 patients diagnosed with moderate to severe
Parkinson’s disease psychosis, which showed that NUPLAZID was a
well-tolerated and effective treatment in these patients.
As part of this statement, ACADIA is providing updated safety
information from two recent clinical studies. Following the approval of
NUPLAZID for the treatment of hallucinations and delusions associated
with Parkinson’s disease psychosis, ACADIA has conducted two
placebo-controlled clinical studies in an aggregate of more than 300
patients with Alzheimer’s disease (AD). In these controlled studies in
frail elderly patients with dementia, there was no difference in the
number of deaths reported between NUPLAZID (four) and placebo (four).
In addition, ACADIA has completed or is in the process of completing all
of the postmarketing commitments included with the NUPLAZID approval
letter, in full compliance with the timelines defined by the FDA.
Of the approximately one million individuals in the United States living
with Parkinson’s disease, over 50 percent will experience hallucinations
and delusions associated with Parkinson’s disease psychosis over the
course of their disease. NUPLAZID fills a significant, previously unmet
need in the treatment of Parkinson’s disease psychosis. Patients and
healthcare professionals recognize the value of NUPLAZID, and we receive
positive feedback about the benefits it provides to patients and their
families. We look forward to working closely and expeditiously with the
FDA and the Parkinson’s disease community to ensure the best and safest
care of patients with Parkinson’s disease psychosis. We thank healthcare
providers for their ongoing support in raising awareness around this
debilitating condition and take pride in the meaningful impact NUPLAZID
has made in the lives of patients with Parkinson’s disease psychosis and
the people who care for them.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines to address unmet medical needs in central nervous system
disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release
that are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to statements
related to benefits to be derived from NUPLAZID (pimavanserin),
the outcome of any ongoing or future evaluation by the FDA of NUPLAZID,
or the timing or results of any future studies with NUPLAZID. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization, and the fact that past results of clinical trials may
not be indicative of future trial results. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K for
the year ended December 31, 2017 as well as ACADIA’s subsequent filings
with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
Important Safety Information and Indication for
NUPLAZID (pimavanserin) tablets
MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
patients with dementia-related psychosis treated with antipsychotic
drugs are at an increased risk of death. NUPLAZID is not approved for
the treatment of patients with dementia-related psychosis unrelated to
the hallucinations and delusions associated with Parkinson’s disease
NUPLAZID is an atypical antipsychotic indicated for the treatment of
hallucinations and delusions associated with Parkinson’s disease
Contraindication: NUPLAZID is contraindicated in patients with a history
of a hypersensitivity reaction to pimavanserin or any of its components.
Rash, urticaria, and reactions consistent with angioedema (e.g., tongue
swelling, circumoral edema, throat tightness, and dyspnea) have been
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of
NUPLAZID should be avoided in patients with known QT prolongation or in
combination with other drugs known to prolong QT interval including
Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain
antipsychotic medications, and certain antibiotics. NUPLAZID should also
be avoided in patients with a history of cardiac arrhythmias, as well as
other circumstances that may increase the risk of the occurrence of
torsade de pointes and/or sudden death, including symptomatic
bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2%
for NUPLAZID and greater than placebo) were peripheral edema (7%
vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination
(5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Strong CYP3A4 inhibitors (e.g., ketoconazole)
increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half.
Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced
efficacy. Increase in NUPLAZID dosage may be needed.
Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and
should therefore be used in pregnancy only if the potential benefit
justifies the potential risk to the mother and fetus.
Pediatric Use: Safety and efficacy have not been established in
Dosage and Administration: Recommended dose: 34 mg per day, taken orally
as two 17-mg tablets once daily, without titration.
For additional Important Safety Information, including boxed warning,
please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180427005265/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Bob Laverty, (609) 558-5570